The North America Anticoagulant Reversal Drugs Market would witness market growth of 12.5% CAGR during the forecast period (2021-2027). Doctors recommend Anticoagulant reversal drugs when anticoagulant therapy of a patient should be reversed or neutralized.
It mostly occurs when there are bleeding complications and, in such cases, an overdose of anticoagulant drug therapy is given. Oral anticoagulants are used to treat blood-related disorders. It is extremely beneficial in reducing the risk of thromboembolism in AFib patients. The dose of anticoagulants can cause bleeding in AFib patients and they are suggested to take anticoagulant reversal drugs that can prevent excessive bleeding.
Bleeding is sometimes a complicated condition for all anticoagulant therapy. Sometimes, it can lead to chronic debilitating conditions or even death. The possibility of hemorrhage is likely to be associated with the intake of anticoagulation. The risk of bleeding may also be increased with antiplatelet medication, cyclooxygenase type-2 inhibitors, and non-steroidal anti-inflammatory agent treatment. When bleeding is excess and it becomes life-threatening, then anticoagulant reversal drugs are given. It is also used when anticoagulant activity needs to be reversed prior to any surgery. The risk of bleeding versus thromboembolism must be evaluated for each specific patient.
According to the “Global Health and Wellness Report”, in the USA more than 40% of the adult population were suffering from cardiovascular disease in 2018. Moreover, it is also estimated by the heart disease and Stroke Statistics 2019 that 1 out of 3 individuals in the United States is vulnerable to lifetime risk of atrial fibrillation. Thus, the increasing number of cardiovascular diseases is expected to be a big burden on the health care system. It will act as a major factor for the growing demand for anticoagulant reversal drugs in this region and will drive the growth of the market in the coming years. Manufacturers of the anticoagulant reversal drugs market are well aware of the increasing demand and thus navigating their research & development to increase the development of these drugs. These aspects would boost the growth of the market in the region.
The US market dominated the North America Retail Pharmacy Market by Country in 2020, and would continue to be a dominant market till 2027. The Canada market is experiencing a CAGR of 14.9% during (2021-2027). Additionally, The Mexico market would witness a CAGR of 13.9% during (2021-2027).
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Product Type, the market is segmented into Idarucizumab, Andexanet Alfa, Prothrombin Complex Concentrates, Phytonadione, Protamine and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Anticoagulant Reversal Drugs Market is Estimated to Reach USD 1.6 Billion by 2027 at a CAGR of 13.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, CSL Limited, Bausch Health Companies, Inc., Octapharma AG, Pfizer, Inc., Fresenius SE & Co. KGaA, Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals), Dr. Reddy’s Laboratories Ltd., AMAG Pharmaceuticals, Inc. (Covis Pharma), and Alps Pharmaceutical Ind. Co., Ltd.
By Distribution Channel
By Product Type
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 